Stratos Wealth Partners LTD. Decreases Stock Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Stratos Wealth Partners LTD. reduced its stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 7.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 310,000 shares of the company's stock after selling 25,840 shares during the period. Stratos Wealth Partners LTD. owned 0.57% of Zevra Therapeutics worth $2,322,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD grew its position in Zevra Therapeutics by 51.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,565 shares of the company's stock valued at $172,000 after buying an additional 6,966 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Zevra Therapeutics during the 4th quarter worth $53,000. Millennium Management LLC boosted its position in shares of Zevra Therapeutics by 138.2% during the 4th quarter. Millennium Management LLC now owns 233,132 shares of the company's stock worth $1,944,000 after purchasing an additional 135,246 shares in the last quarter. Deutsche Bank AG boosted its position in shares of Zevra Therapeutics by 25.4% during the 4th quarter. Deutsche Bank AG now owns 50,906 shares of the company's stock worth $425,000 after purchasing an additional 10,306 shares in the last quarter. Finally, ProShare Advisors LLC purchased a new stake in shares of Zevra Therapeutics during the 4th quarter worth $145,000. 35.03% of the stock is currently owned by hedge funds and other institutional investors.

Zevra Therapeutics Trading Up 4.2%

Shares of NASDAQ ZVRA traded up $0.51 on Friday, reaching $12.53. 1,626,224 shares of the company traded hands, compared to its average volume of 715,848. Zevra Therapeutics, Inc. has a fifty-two week low of $5.45 and a fifty-two week high of $12.55. The company has a 50 day moving average of $9.06 and a 200 day moving average of $8.21. The company has a current ratio of 3.02, a quick ratio of 2.93 and a debt-to-equity ratio of 1.46. The stock has a market capitalization of $685.14 million, a PE ratio of -6.59 and a beta of 1.97.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.15. Zevra Therapeutics had a negative net margin of 226.78% and a negative return on equity of 201.05%. The company had revenue of $20.40 million during the quarter, compared to the consensus estimate of $16.96 million. During the same quarter in the prior year, the company posted ($0.40) EPS. On average, equities research analysts forecast that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Citigroup restated an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, May 14th. Cantor Fitzgerald boosted their target price on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the stock an "overweight" rating in a research report on Thursday. Wall Street Zen upgraded shares of Zevra Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Finally, HC Wainwright began coverage on Zevra Therapeutics in a research note on Wednesday, July 2nd. They set a "buy" rating and a $26.00 price target for the company. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Zevra Therapeutics currently has an average rating of "Buy" and a consensus target price of $23.71.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.